Search

Your search keyword '"Candi, V."' showing total 2 results
Start Over Author "Candi, V." Journal anti cancer agents in medicinal chemistry
2 results on '"Candi, V."'

1. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.

Author

Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, and Bocchia M

Subjects
Adenine analogs & derivatives, Agammaglobulinaemia Tyrosine Kinase, Antineoplastic Agents chemistry, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Humans, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Molecular Structure, Piperidines, Protein Kinase Inhibitors chemistry, Protein-Tyrosine Kinases metabolism, Pyrazoles chemistry, Pyrimidines chemistry, Structure-Activity Relationship, Antineoplastic Agents pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Protein Kinase Inhibitors pharmacology, Protein-Tyrosine Kinases antagonists & inhibitors, Pyrazoles pharmacology, Pyrimidines pharmacology
Abstract

Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton's tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)

Published
2017
Full Text
View/download PDF

2. Second Generation Proteasome Inhibitors in Multiple Myeloma.

Author

Gozzetti A, Papini G, Candi V, Brambilla CZ, Sirianni S, and Bocchia M

Subjects
Animals, Boronic Acids pharmacology, Boronic Acids therapeutic use, Bortezomib pharmacology, Bortezomib therapeutic use, Central Nervous System Neoplasms metabolism, Drug Discovery, Humans, Lactones pharmacology, Lactones therapeutic use, Multiple Myeloma metabolism, Neoplasm Recurrence, Local drug therapy, Oligopeptides pharmacology, Oligopeptides therapeutic use, Proteasome Inhibitors pharmacology, Pyrroles pharmacology, Pyrroles therapeutic use, Threonine analogs & derivatives, Threonine pharmacology, Threonine therapeutic use, Central Nervous System Neoplasms drug therapy, Multiple Myeloma drug therapy, Proteasome Inhibitors therapeutic use
Abstract

Bortezomib was the first proteasome inhibitor (PI) discovered and demonstrated great efficacy in myeloma, both in vitro and in patients. However, still many patients ultimately relapse and there is the need for novel therapies. A second generation of PI have been discovered, potentially more effective ands some also orally administered. Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies. Ixazomib is an oral compound that has been introduced recently in the therapeutic spectrum. Novel agents such as Marizomib seem promising in the fact that can also pass through the blood brain barrier and maybe effective also in CNS muyeloma. This review focus on all proteasome inhibitors available in clinics and the new ones coming soon., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results